The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
- Investigator
- Mohammed Ruzieh
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All